Home »

SUBSCRIBE TO NEWSLETTERS

SPECIALTIES
Meeting Coverage
DEEP DIVES
CME/CE
MEDIA & RESOURCES
SUBSCRIBE TO NEWSLETTERS
CONTRIBUTE
Follow Us

Search

Advertisement

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

Apr 5, 2022

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

Click to read this study in JAMA Oncology.

Author

admin

View all posts

For latest news and updates

Email-id is invalid

The Company

About Physician’s Weekly

Memberships & Verifications

Work With PW

Advertise With Us

Our Policies

Terms & Conditions

Editorial Policy

Connect With PW

Explore Our Network

Follow Us

Subscribe

For latest news and updates

Email-id is invalid

The content of this site is intended for healthcare professionals.

© 2024 Physician’s Weekly, a Formedics Property

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Physician’s Weekly, their employees, and affiliates.